NCT01416987View on ClinicalTrials.gov

A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa)

CompletedOBSERVATIONAL

Enrollment

600

Participants

Timeline

Start Date

August 14, 2011

Primary Completion Date

May 10, 2018

Study Completion Date

May 10, 2018

Conditions

Infertility

Interventions

DRUG

Pergoveris®

Participants received once daily injection of a single vial of Pergoveris® which contained 150 International Units (IU) of follitropin alfa (r-hFSH) and 75 IU of lutropin alfa (r-hLH), for approximately 8 days.

Trial Locations (2)

04619

Research site, Seoul

05505

Research site, Seoul

All Listed Sponsors

collaborator

Merck Ltd.

INDUSTRY

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01416987 - A Korean Post-Marketing Surveillance Study On Pergoveris® (Follitropin Alfa + Lutropin Alfa) | Biotech Hunter | Biotech Hunter